Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Huai‐Qiang Ju

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1713-5465; OpenAlex author ID A5050581018. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 7

  1. Corrigendum to "Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer [Cancer Lett. 379 (2016) 1-11]. Co-author DOI 10.1016/j.canlet.2025.217562↗
  2. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation. Co-author DOI 10.1016/j.canlet.2017.09.018↗
  3. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncomms14437↗
  4. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.05.024↗
  5. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation. Co-author DOI 10.1111/jpi.12285↗
  6. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. First author DOI 10.1158/1078-0432.ccr-14-3382↗
  7. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation. Co-author DOI 10.1158/1535-7163.mct-14-0420↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul J. Chiao · 7 shared papers, 2015–2025 · strength 0.56
  2. Rui‐Hua Xu · 4 shared papers, 2016–2025 · strength 0.40
  3. Yun‐Xin Lu · 3 shared papers, 2016–2025 · strength 0.35
  4. Jie Fu · 4 shared papers, 2015–2017 · strength 0.21
  5. Zhuonan Zhuang · 3 shared papers, 2016–2017 · strength 0.16
  6. Jianhua Ling · 3 shared papers, 2016–2017 · strength 0.16
  7. Lu Yu · 2 shared papers, 2017 · strength 0.11
  8. Peng Huang · 2 shared papers, 2015–2017 · strength 0.10
  9. Lifeng Yang · 1 shared paper, 2017 · strength 0.05
  10. Huamin Wang · 1 shared paper, 2017 · strength 0.05
  11. Jun Yao · 1 shared paper, 2017 · strength 0.05
  12. Haoqiang Ying · 1 shared paper, 2017 · strength 0.05
  13. Ronald Anthony Depinho · 1 shared paper, 2017 · strength 0.05
  14. Mien‐Chie Hung · 1 shared paper, 2017 · strength 0.05
  15. Deepak Nagrath · 1 shared paper, 2017 · strength 0.05
  16. Wuguo Deng · 1 shared paper, 2016 · strength 0.05
  17. Takeshi Gocho · 1 shared paper, 2015 · strength 0.05
  18. Katsuhiko K. Yanaga · 1 shared paper, 2015 · strength 0.05
  19. Xiaoqiang Fan · 1 shared paper, 2016 · strength 0.05
  20. Min Li · 1 shared paper, 2016 · strength 0.05
  21. Jason B. Fleming · 1 shared paper, 2016 · strength 0.05
  22. Davide Melisi · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.